- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07188558
- Original retssag
En undersøgelse til undersøgelse (PiNACLE-H2H)
Et fase 3 randomiseret kontrolleret forsøg med Rondecabtagene Autoleucel, en autolog, dobbeltmålrettet CD19/CD20 CAR T-celle produktkandidat, versus efterforskerens valg af CD19 CAR T-cellebehandling hos patienter med tilbagefaldt eller refraktær stort B-celle lymfom i den anden-line indstilling CD19
This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
PiNACLE-H2H is a Phase 3 randomized controlled trial comparing the efficacy and safety of rondecabtagene autoleucel (ronde-cel, formerly known as LYL314) against the currently approved cluster of differentiation (CD)19 chimeric antigen receptor (CAR) T-cell therapies (axicabtagene ciloleucel [axi-cel] or lisocabtagene maraleucel [liso-cel]), in patients with aggressive LBCL that has relapsed or is refractory to first-line anti-CD20 antibody and anthracycline-containing chemotherapy.
Patients will be randomized (1:1) before leukapheresis to receive either:
- Ronde-cel; or
- Investigator's choice of axi-cel or liso-cel
Most patients who receive currently approved CD19-directed CAR T-cell therapies, including axi-cel and liso-cel, still experience progressive disease, often due to mechanisms such as CD19 antigen loss or T-cell exhaustion.
Ronde-cel is a novel, autologous, dual-targeting CD19/CD20 CAR T-cell product candidate enriched for CD62L-positive naïve and central memory T cells, which are associated with enhanced proliferation capacity and persistence. Ronde-cel is an "OR"-gated CAR construct that can fully activate upon recognition of either CD19 or CD20, aiming to improve durability of response despite antigen heterogeneity.
Approximately 400 participants will be enrolled. CAR T-cell therapy in both arms will be administered as a single intravenous infusion following fludarabine and cyclophosphamide lymphodepletion. Participants will be followed for 3 years for safety and efficacy, with long-term follow-up extending to 15 years.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Mary Lessig, MS
- Telefonnummer: 000-000-0000
- E-mail: clinicaltrials@lyell.com
Undersøgelse Kontakt Backup
- Navn: James Dean, MD, PhD
- Telefonnummer: 000-000-0000
- E-mail: clinicaltrials@lyell.com
Studiesteder
-
-
Queensland
-
Douglas, Queensland, Australien, 4814
- Rekruttering
- Townsville University Hospital
-
-
Victoria
-
Melbourne, Victoria, Australien, 3004
- Rekruttering
- The Alfred
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- Rekruttering
- Princess Margaret Cancer Centre
-
-
-
-
Arizona
-
Gilbert, Arizona, Forenede Stater, 85234
- Rekruttering
- Banner MD Anderson Cancer Center
-
Scottsdale, Arizona, Forenede Stater, 85258
- Rekruttering
- Honor Health
-
Scottsdale, Arizona, Forenede Stater, 85259
- Rekruttering
- Mayo Clinic Arizona
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72205
- Ikke rekrutterer endnu
- University of Arkansas
-
-
California
-
Los Angeles, California, Forenede Stater, 90048
- Rekruttering
- Cedars-Sinai Medical Center
-
Los Angeles, California, Forenede Stater, 90095
- Rekruttering
- University of California, Los Angeles (UCLA)
-
Orange, California, Forenede Stater, 92868
- Rekruttering
- University of California, Irvine
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Rekruttering
- University of Colorado
-
Denver, Colorado, Forenede Stater, 80218
- Rekruttering
- Colorado Blood Cancer Institute
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20007
- Rekruttering
- MedStar Georgetown University Hospital
-
-
Florida
-
Jacksonville, Florida, Forenede Stater, 32224
- Rekruttering
- Mayo Clinic Florida
-
Orlando, Florida, Forenede Stater, 32804
- Rekruttering
- AdventHealth
-
Tampa, Florida, Forenede Stater, 33612
- Rekruttering
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30342
- Rekruttering
- Northside Hospital
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60637
- Rekruttering
- University of Chicago
-
Chicago, Illinois, Forenede Stater, 60611
- Rekruttering
- Northwestern
-
-
Iowa
-
Iowa City, Iowa, Forenede Stater, 52242
- Rekruttering
- University of Iowa
-
-
Kansas
-
Westwood, Kansas, Forenede Stater, 66205
- Rekruttering
- University of Kansas Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, Forenede Stater, 40202
- Rekruttering
- University of Louisville Health
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02111
- Rekruttering
- Tufts Medical Center
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905
- Rekruttering
- Mayo Clinic Rochester
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68105
- Rekruttering
- University of Nebraska Medical Center (UNMC)
-
-
New Jersey
-
Hackensack, New Jersey, Forenede Stater, 07601
- Rekruttering
- Hackensack
-
Morristown, New Jersey, Forenede Stater, 07960
- Rekruttering
- Atlantic Health
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87102
- Rekruttering
- University of New Mexico Comprehensive Cancer Center
-
-
New York
-
Buffalo, New York, Forenede Stater, 14263
- Rekruttering
- Roswell Park Comprehensive Cancer Center
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 27705
- Rekruttering
- Duke Cancer Institute
-
Winston-Salem, North Carolina, Forenede Stater, 27157
- Ikke rekrutterer endnu
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45267
- Rekruttering
- University of Cincinnati
-
Cincinnati, Ohio, Forenede Stater, 45242
- Rekruttering
- Oncology Hematology Care Clinical Trials
-
Cleveland, Ohio, Forenede Stater, 44195
- Rekruttering
- Cleveland Clinical Taussig Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15212
- Ikke rekrutterer endnu
- Allegheny Health Network
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- SCRI Oncology Partners
-
-
Texas
-
Austin, Texas, Forenede Stater, 78704
- Rekruttering
- St. David's South Austin Medical Center
-
Fort Worth, Texas, Forenede Stater, 76104
- Rekruttering
- University of Texas Southwestern Medical Center
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- MD Anderson Cancer Center
-
San Antonio, Texas, Forenede Stater, 78229
- Rekruttering
- Texas Transplant Institute
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84143
- Rekruttering
- Intermountain Healthcare
-
-
Virginia
-
Norfolk, Virginia, Forenede Stater, 23502
- Rekruttering
- Virginia Oncology Associates
-
Richmond, Virginia, Forenede Stater, 23298
- Rekruttering
- Virginia Commonwealth University-Massey Cancer Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Rekruttering
- Medical College of Wisconsin
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
-
CAR T cell naïve and eligible to receive a CD19 CART-cell therapy
-
Histologically confirmed large B-cell lymphoma, including the following types defined by (WHO 2022) or International Consensus Classification (2022)
- Diffuse large B-cell lymphoma (DLBCL)
- Transformations of indolent B-cell lymphomas (excluding Richter's transformation)
- DLBCL/High-grade B-cell lymphoma (HGBCL) with MYC and BCL2 rearrangements
- High-grade B-cell lymphoma (HGBCL) not otherwise specified (HGBCL NOS)
- Primary mediastinal large B-cell lymphoma (PMBCL)
- Grade 3B follicular lymphoma/large cell follicular lymphoma (FL3B)
-
Relapsed or refractory disease after anti-CD20 antibody and anthracycline-containing first-line chemoimmunotherapy
-
Measurable disease by presence of [18F]-fluorodeoxyglucose PET/CT positive lesion during Screening per Lugano Criteria
-
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
-
Adequate hematological, renal, hepatic, pulmonary, and cardiac function
Key Exclusion Criteria:
- Patients ineligible to receive CD19 CAR T-cell therapy
- Primary CNS lymphoma
- Patients with primary cutaneous LBCL, human herpes virus-8 positive lymphoma, Burkitt lymphoma, T cell histiocyte-rich lymphoma, or transformation from chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter's transformation)
- Patients with prior history of malignancy, other than aggressive relapsed or refractory LBCL, unless the patient has been free of the disease for ≥ 2 years
- Patients with uncontrolled systemic fungal, bacterial, viral, or other infection (including tuberculosis) despite appropriate antibiotics or other treatment
- Active autoimmune disease requiring ongoing systemic immunosuppressive therapy.
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Rondecabtagene Autoleucel
|
An autologous, dual-targeting CD19/20 CAR T-cell candidate.
Andre navne:
|
|
Aktiv komparator: Investigator's Choice CD19
axicabtagene ciloleucel, lisocabtagene maraleucel |
An autologous CD19 CAR T-cell therapy
Andre navne:
An autologous CD19 CAR T-cell therapy
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Event free survival
Tidsramme: 36 months
|
The time interval from treatment initiation until the occurrence of a specific event of interest. |
36 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Response Rate
Tidsramme: 36 months
|
Best Overall Response per Lugano Criteria |
36 months
|
|
Complete Response Rate
Tidsramme: 36 months
|
Complete Response per Lugano Criteria |
36 months
|
|
Progression Free Survial
Tidsramme: 36 months
|
The length of time during and after the treatment of a disease that a patient lives with the disease but it does not get worse. |
36 months
|
|
Overall Survival
Tidsramme: 6 years
|
The length of time from either the date of diagnosis or the start of treatment for a disease, that patients diagnosed with the disease, are still alive. |
6 years
|
|
Incidence and severity adverse events
Tidsramme: 36 months
|
To assess safety defined as type and frequency of AEs, serious adverse events (SAEs), and laboratory abnormalities. |
36 months
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- LYL314-102
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .